Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus NAFCILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus NAFCILLIN SODIUM.
LAROTID vs NAFCILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic